This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bereczki, D. Articles by Lee, R. T. Search for Related Content PubMed PubMed Citation Articles by Bereczki, D. Articles by Lee, R. T.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1129.)
© 2003 American Heart Association, Inc.

Letters to the Editor

Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples?

Dániel Bereczki; Emõke Nagy; András Pál; Mária T. Magyar; József Balla

Departments of Neurology (D.B., M.T.M.) and Internal Medicine (E.N., J.B.), University of Debrecen, Health Science and Medical Center, Debrecen, and Sanofi-Synthelabo Co, Ltd (A.P.), Budapest, Hungary

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

We were surprised to read the article by Blake et al¹ on the relationship of soluble CD40 ligand (sCD40L) and lipid accumulation in carotid atheroma. We recently reported an association between inflammatory markers and early onset carotid atherosclerosis.² Of the patients noted in that report, we had plasma samples from EDTA-anticoagulated blood, stored frozen for 1 to 3 years. Although the product information and manual of the Bender MedSystem’s ELISA kit clearly states that plasma preparations are not suitable for the essay,³ we decided to run a test on some of these plasma samples for sCD40L. We also used duplicate plasma samples, together with fresh serum and plasma of 5 healthy subjects obtained less than 4 hours before the ELISA test, in the same ELISA plate. We were not surprised but were disappointed, as no activity could be detected either in the frozen plasma samples of patients or in the fresh or recalcified plasma samples of the healthy subjects. The method and the plate worked properly, as sCD40L activity was measured with small variation between duplicates in all of the serum samples (7.0±1.5 ng/mL, mean±SD). We had to conclude and admit that, as stated in the product information, EDTA-anticoagulated plasma samples—either frozen or freshly collected—are not appropriate for the test.

After this failure, we came across the article of Blake et al,¹ in which the authors referred to their previous report for the method of sCD40L determination.⁴ They used plasma samples from EDTA-anticoagulated blood, and the same . . . [Full Text of this Article]

Gavin J. Blake; Robert J. Ostfeld; E. Kent Yucel; Nerea Varo; Uwe Schonbeck; Michael A. Blake; Marie Gerhard; Paul M. Ridker; Peter Libby; Richard T. Lee

Cardiovascular Division (G.J.B., R.J.O., E.K.Y., M.G., P.M.R., P.L., R.T.L.) and the Leducq Center for Cardiovascular Research (G.J.B., R.J.O., N.V., U.S., M.G., P.M.R., P.L., R.T.L.), Brigham and Women’s Hospital, and the Department of Radiology (M.A.B.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass

This article has been cited by other articles:

				M. Plaikner, A. Peer, G. Falkensammer, C. Schmidauer, C. Pechlaner, A. Griesmacher, O. Pachinger, and J. Mair Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department Clin. Chem., January 1, 2009; 55(1): 175 - 178. [Abstract] [Full Text] [PDF]

				B. T. Ivandic, E. Spanuth, D. Haase, H.-G. Lestin, and H. A. Katus Increased Plasma Concentrations of Soluble CD40 Ligand in Acute Coronary Syndrome Depend on in Vitro Platelet Activation Clin. Chem., July 1, 2007; 53(7): 1231 - 1234. [Abstract] [Full Text] [PDF]

				F. Martino, P. Pignatelli, E. Martino, F. Morrone, R. Carnevale, S. Di Santo, B. Buchetti, L. Loffredo, and F. Violi Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1974 - 1981. [Abstract] [Full Text] [PDF]

				Y Allanore, D Borderie, C Meune, H Lemarechal, S Weber, O G Ekindjian, and A Kahan Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers Ann Rheum Dis, March 1, 2005; 64(3): 481 - 483. [Abstract] [Full Text] [PDF]

				S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation, July 27, 2004; 110(4): 386 - 391. [Abstract] [Full Text] [PDF]